This pattern recognition tool runs Inverted Hammer recognition and companion studies for Evaxion Biotech. Signals here center on pattern recognition signals tied to momentum and continuation alongside volatility and performance references.
This analysis covers fifty data points across the selected time horizon. The function generated a total of one valid pattern recognition events for the selected time horizon. The Inverted Hammer pattern indicates that the buyers drove prices of Evaxion Biotech AS up, at some point during the period, but encountered selling pressure which drove prices back down to close near to where they opened.
Evaxion Biotech Technical Analysis Modules
Most technical analysis of Evaxion Biotech help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Evaxion from various momentum indicators to cycle indicators. When you analyze Evaxion charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Evaxion Biotech AS, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company was incorporated in 2008 and is headquartered in Hrsholm, Denmark. Evaxion Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 61 people. The stock overview for Evaxion Biotech summarizes business drivers, financial profile, and market behavior. The company is positioned within Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Current metrics include P/B of 2.14, profit margin of -102.38%. Evaxion Biotech has a market cap of 35.53 M, ROE of -100.18%.
Methodology
Unless otherwise specified, financial data for Evaxion Biotech AS is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Evaxion (USA Stocks:EVAX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: This report is built using public filings and market reference sources and official sources including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Normalization for analytical consistency may introduce small timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Evaxion Biotech AS has active sell-side coverage. Source-validated coverage currently shows 4 approved analysts, while broader market-consensus totals may differ across providers due to methodology and update timing. 2 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Bernstein Research, Deutsche Bank, Morgan Stanley, BMO Capital Markets, Guggenheim Securities, among others. Updates may occur throughout the day.
Performance tracking around Evaxion Biotech AS should go beyond the latest gain or loss and focus on how the position changes overall portfolio efficiency over time. This is most helpful when investors want a consistent framework for balancing conviction with risk control.
Generate Optimal Portfolios
Align your risk and return expectations
Risk tolerance and time horizon inputs allow Macroaxis optimization to estimate acceptable risk levels. The output provides a structured risk context for return targets.
Understanding Evaxion Biotech AS typically begins with financial statements and long-term trend review. Ratios and trend metrics help frame Evaxion Biotech's operating context across reporting periods. Key reports that frame Evaxion Biotech AS Stock are listed below:
Evaxion Biotech has a market cap of 35.53 M, operating margin of -122.66%, ROE of -100.18%. See Investing Opportunities for portfolio-level analysis. This reflects a position in Evaxion Biotech AS within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Evaxion Biotech currently shows ROE of -100.18%, market cap of 35.53 Million. Evaxion Biotech data on this page supports broader research - the resources below add portfolio-level context. For Evaxion Biotech, the analytical tools below add portfolio-level context that single-security review alone cannot provide. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Earnings Share
-1.00
Revenue Per Share
1.175
Return On Assets
-0.28
Return On Equity
-1.00
The market value of Evaxion Biotech AS is measured differently than book value, which reflects Evaxion accounting equity. Evaxion Biotech's market capitalization is 35.53 M. A P/B ratio of 2.14 indicates the market values Evaxion Biotech above its accounting book value. Enterprise value stands at 20.72 M. Intrinsic value reflects what Evaxion Biotech's fundamentals imply about worth, which may differ from both the trading price and the book figure. Analytical frameworks help reconcile those views.
It is useful to distinguish Evaxion Biotech's value from its trading price, which are computed with different methods. For Evaxion Biotech, key inputs include a P/B ratio of 2.14, a profit margin of -102.38%, ROE of -100.18%, and revenue of 7.55 M. Evaxion Biotech's market quotation reflects the latest level where a willing buyer met a willing seller.